2024-05-29 02:16:04 ET
Summary
- Stevanato revised its guidance for 2024 due to weaker-than-expected orders and clients' destocking activities.
- The company's Q1 results show decreased EBITDA and profit, causing investors to sell off shares.
- Here at the Lab, we remain confident in long-term prospects thanks to capacity expansion and biologics demand.
- STVN is not trading at a premium compared to its peers. Therefore, we reinstated a buy rating status.
In our last assessment, we decided to lower Stevanato Group's ( STVN ) rating due to ' Destocking And Valuation Risk . ' As a reminder, having checked Stevanato's peers' lower sales growth estimates in 2024 and anticipating a decline in EBITDA and net profit due to start-up costs and an unfavorable exchange rate effect, the company's valuation was full in our view....
Read the full article on Seeking Alpha
For further details see:
Stevanato: Destock Pressures, Long-Term Upside